The current financial score of Edwards Lifesciences Corp is 9.52. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.74B, representing a year-over-year increase of 13.63%, while its net profit experienced a year-over-year increase of 27.40%.
The current valuation score of Edwards Lifesciences Corp is 6.90. Its current P/E ratio is 46.95, which is 7.67% below the recent high of 50.55 and 80.14% above the recent low of 9.32.
The current earnings forecast score of Edwards Lifesciences Corp is 8.26. The average price target is 99.60, with a high of 110.00 and a low of 85.00.
The current price momentum score of Edwards Lifesciences Corp is 2.86. Currently, the stock price is trading between the resistance level at 90.98 and the support level at 84.12, making it suitable for range-bound swing trading.
The current institutional shareholding score of Edwards Lifesciences Corp is 10.00. The latest institutional shareholding proportion is 93.71%, representing a quarter-over-quarter increase of 0.19%.
The current risk assessment score of Edwards Lifesciences Corp is 9.06. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.